Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Clinical trial NCT04074967 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04074967
Sponsor: Dan Zandberg
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Renal Cell Carcinoma Melanoma Solid Tumor Non-small Cell Lung Cancer Head and Neck Squamous Cell Carcinoma

Start date: 2020-06-11
Primary completion: 2024-12-27
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.